GlassScriptPhysician profile
Julian E Armstrong
NPI 1972594745
$3,725.17
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $281 · 2021: $555 · 2022: $917 · 2023: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970 · Education: $44.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $970.30 |
| Education | $44.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,216.73 | 2019-2023 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $335.86 | 2019-2023 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.36 | 2019-2023 | Xifaxan |
| Janssen Biotech, INC. | $256.24 | 2019-2023 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $204.36 | 2019-2023 | |
| Celgene Corporation | $200.70 | 2021-2023 | Zeposia |
| Qol Medical, LLC | $178.39 | 2019-2021 | |
| Abbott Laboratories | $128.40 | 2022 | |
| Ironwood Pharmaceuticals, INC | $84.02 | 2021-2023 | Linzess |
| Regeneron Healthcare Solutions, INC. | $74.62 | 2023 | Dupixent |
| Genzyme Corporation | $74.36 | 2023 | |
| Daiichi Sankyo INC. | $71.43 | 2019-2022 | |
| Braintree Laboratories, INC. | $69.04 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $68.57 | 2021-2023 | Dificid, Zinplava |
| Janssen Scientific Affairs, LLC | $64.00 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $56.12 | 2021-2023 | Movantik, Aemcolo, Talicia |
| Ethicon US, LLC | $52.44 | 2019-2020 | |
| Allergan, INC. | $51.99 | 2019-2020 | |
| Organon LLC | $51.58 | 2021-2023 | Renflexis |
| Intercept Pharmaceuticals, INC. | $46.99 | 2022-2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $36.26 | 2020-2022 | |
| Ardelyx, INC. | $26.97 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.34 | 2022 | |
| Gi Supply, INC. | $21.68 | 2022 | |
| Shionogi INC | $17.47 | 2019 | |
| Nestle Healthcare Nutrition INC. | $17.39 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.15 | 2021 | |
| Medtronic, INC. | $12.71 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julian Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.